Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics is a clinical-stage bioresearch company developing IRX-2, a new immunotherapy for cancer.


Brooklyn ImmunoTherapeutics is developing novel immunotherapies based upon reversing immune suppression typically seen in patients with cancer and other diseases by activating and stimulating multiple components of the cellular immune system. Brooklyn ImmunoTherapeutics’ extensive research science leads us to believe this will result in immune system recognition of and activation against disease.

Brooklyn ImmunoTherapeutics’ lead product, IRX-2, is a primary cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.

News from Disruptive capital GP Limited